The time for cardiovascular inflammation reduction trials has arrived: how low to go for hsCRP?
Paul M
PM
Ridker
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism*; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D003327:Coronary Disease / Q000097:blood / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D006801:Humans; D015994:Incidence; D007249:Inflammation / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D015854:Up-Regulation
D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D002317:Cardiovascular Agents; D002097:C-Reactive Protein